85 related articles for article (PubMed ID: 24476739)
1. Triple-negative breast cancer: what is known about it?
Ferguson LL; Curran B; Martinez M; Mancuso P
Clin J Oncol Nurs; 2014 Feb; 18(1):E6-E11. PubMed ID: 24476739
[TBL] [Abstract][Full Text] [Related]
2. Triple-negative breast cancer survival in Iranian patients.
Aghili M; Lashkari M; Farrokhpey AH; Izadi S
Acta Med Iran; 2013 Sep; 51(8):560-6. PubMed ID: 24026994
[TBL] [Abstract][Full Text] [Related]
3. Breast-conserving therapy for triple-negative breast cancer.
Gangi A; Chung A; Mirocha J; Liou DZ; Leong T; Giuliano AE
JAMA Surg; 2014 Mar; 149(3):252-8. PubMed ID: 24382582
[TBL] [Abstract][Full Text] [Related]
4. Triple-negative breast cancer in Hispanic patients: high prevalence, poor prognosis, and association with menopausal status, body mass index, and parity.
Lara-Medina F; Pérez-Sánchez V; Saavedra-Pérez D; Blake-Cerda M; Arce C; Motola-Kuba D; Villarreal-Garza C; González-Angulo AM; Bargalló E; Aguilar JL; Mohar A; Arrieta Ó
Cancer; 2011 Aug; 117(16):3658-69. PubMed ID: 21387260
[TBL] [Abstract][Full Text] [Related]
5. Co-expression of cancer testis antigens and topoisomerase 2-alpha in triple negative breast carcinomas.
Mrklić I; Spagnoli GC; Juretić A; Pogorelić Z; Tomić S
Acta Histochem; 2014 Jun; 116(5):740-6. PubMed ID: 24560456
[TBL] [Abstract][Full Text] [Related]
6. New targets for triple-negative breast cancer.
Herold CI; Anders CK
Oncology (Williston Park); 2013 Sep; 27(9):846-54. PubMed ID: 24282978
[TBL] [Abstract][Full Text] [Related]
7. [Comparison of biological behavior between triple-negative breast cancer and non-triple- negative breast cancer].
Ma JG; Wang NJ; Yu WJ
Nan Fang Yi Ke Da Xue Xue Bao; 2011 Oct; 31(10):1729-32. PubMed ID: 22027778
[TBL] [Abstract][Full Text] [Related]
8. [Clinicopathologic features and prognosis of triple negative breast cancer].
Zhou T; Yang L; Ma GM; Li CX; Bai Y; Zhao JA; Wang XL; Geng CZ
Zhonghua Yi Xue Za Zhi; 2009 Aug; 89(32):2261-4. PubMed ID: 20095338
[TBL] [Abstract][Full Text] [Related]
9. Potential role of targeted therapies in the treatment of triple-negative breast cancer.
Jia LY; Shanmugam MK; Sethi G; Bishayee A
Anticancer Drugs; 2016 Mar; 27(3):147-55. PubMed ID: 26682525
[TBL] [Abstract][Full Text] [Related]
10. GPER mediates enhanced cell viability and motility via non-genomic signaling induced by 17β-estradiol in triple-negative breast cancer cells.
Yu T; Liu M; Luo H; Wu C; Tang X; Tang S; Hu P; Yan Y; Wang Z; Tu G
J Steroid Biochem Mol Biol; 2014 Sep; 143():392-403. PubMed ID: 24874276
[TBL] [Abstract][Full Text] [Related]
11. "An addendum to breast cancer": the triple negative experience.
Turkman YE; Kennedy HP; Harris LN; Knobf MT
Support Care Cancer; 2016 Sep; 24(9):3715-21. PubMed ID: 27037812
[TBL] [Abstract][Full Text] [Related]
12. Targeting CD73 and downstream adenosine receptor signaling in triple-negative breast cancer.
Allard B; Turcotte M; Stagg J
Expert Opin Ther Targets; 2014 Aug; 18(8):863-81. PubMed ID: 24798880
[TBL] [Abstract][Full Text] [Related]
13. Integrated analysis of expression profiling data identifies three genes in correlation with poor prognosis of triple-negative breast cancer.
Zhang C; Han Y; Huang H; Min L; Qu L; Shou C
Int J Oncol; 2014 Jun; 44(6):2025-33. PubMed ID: 24676531
[TBL] [Abstract][Full Text] [Related]
14. [Current status and future perspectives for the treatment of triple-negative breast cancer in Japan].
Masuda N; Yasojima H; Mizutani M; Yamamura J
Gan To Kagaku Ryoho; 2012 Apr; 39(4):512-8. PubMed ID: 22504674
[TBL] [Abstract][Full Text] [Related]
15. Triple-negative breast cancer: An institutional analysis.
Gogia A; Raina V; Deo SV; Shukla NK; Mohanti BK
Indian J Cancer; 2014; 51(2):163-6. PubMed ID: 25104201
[TBL] [Abstract][Full Text] [Related]
16. Triple negative breast cancer in Korea-distinct biology with different impact of prognostic factors on survival.
Lee JA; Kim KI; Bae JW; Jung YH; An H; Lee ES;
Breast Cancer Res Treat; 2010 Aug; 123(1):177-87. PubMed ID: 20574671
[TBL] [Abstract][Full Text] [Related]
17. Is androgen receptor targeting an emerging treatment strategy for triple negative breast cancer?
Anestis A; Karamouzis MV; Dalagiorgou G; Papavassiliou AG
Cancer Treat Rev; 2015 Jun; 41(6):547-53. PubMed ID: 25944485
[TBL] [Abstract][Full Text] [Related]
18. Tumor characteristics and recurrence patterns in triple negative breast cancer: a comparison between younger (<65) and elderly (≥65) patients.
Königsberg R; Pfeiler G; Klement T; Hammerschmid N; Brunner A; Zeillinger R; Singer C; Dittrich C
Eur J Cancer; 2012 Nov; 48(16):2962-8. PubMed ID: 22647688
[TBL] [Abstract][Full Text] [Related]
19. Identification of patients with node-negative, triple-negative breast cancer who benefit from adjuvant cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy.
Wu CE; Chen SC; Lin YC; Lo YF; Hsueh S; Chang HK
Anticancer Res; 2014 Mar; 34(3):1301-6. PubMed ID: 24596377
[TBL] [Abstract][Full Text] [Related]
20. [Triple-negative breast cancer: analysis of patients diagnosed and/or treated at the Masaryk Memorial Cancer Institute between 2004 and 2009].
Svoboda M; Navrátil J; Fabian P; Palácová M; Gombošová J; Slámová L; Princ D; Syptáková B; Kudláček A; Bílek O; Pospíšil P; Kazda T; Grell P; Poprach A; Selingerová I; Nenutil R; Juráček J; Héžová R; Slabý O; Vyzula R
Klin Onkol; 2012; 25(3):188-98. PubMed ID: 22724568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
